TherapeuticsMD, Inc.TXMDNASDAQ
Loading
Free Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank90
5Y CAGR+41.6%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+41.6%/yr
Long-term compound
Percentile
P90
Near historical high
vs 5Y Ago
5.7x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 222.84% |
| Q2 2025 | -52.77% |
| Q1 2025 | 5616.67% |
| Q4 2024 | 106.49% |
| Q3 2024 | -120.69% |
| Q2 2024 | 8027.27% |
| Q1 2024 | 0.00% |
| Q4 2023 | 100.00% |
| Q3 2023 | 47.43% |
| Q2 2023 | 85.92% |
| Q1 2023 | -155.54% |
| Q4 2022 | 473.60% |
| Q3 2022 | -91.01% |
| Q2 2022 | 491.74% |
| Q1 2022 | 28.01% |
| Q4 2021 | -6.94% |
| Q3 2021 | -44.27% |
| Q2 2021 | 30.75% |
| Q1 2021 | -24.75% |
| Q4 2020 | 10.19% |
| Q3 2020 | 39.11% |
| Q2 2020 | -42.47% |
| Q1 2020 | 22.68% |
| Q4 2019 | -85.86% |
| Q3 2019 | 46.76% |
| Q2 2019 | -33.16% |
| Q1 2019 | -35.52% |
| Q4 2018 | 47.33% |
| Q3 2018 | -115.37% |
| Q2 2018 | -27.46% |
| Q1 2018 | 6.33% |
| Q4 2017 | -26.26% |
| Q3 2017 | 8.97% |
| Q2 2017 | 10.90% |
| Q1 2017 | -29.05% |
| Q4 2016 | 15.69% |
| Q3 2016 | -20.08% |
| Q2 2016 | 19.19% |
| Q1 2016 | -14.70% |
| Q4 2015 | 7.67% |